COX-2 inhibitors: pharmacological data and adverse effects

Area of Science:

• Pharmacology
• Drug Discovery
• Biochemistry

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) exhibit varying selectivity for cyclooxygenase (COX) enzymes.
• Selective COX-2 inhibitors (coxibs) represent a distinct class with high COX-2 selectivity.
• The initial hypothesis of distinct COX-1 and COX-2 roles requires refinement.

Purpose of the Study:

• To review pharmacological data and side effect profiles of coxibs.
• To analyze the impact of selective COX-2 inhibition on various physiological systems.
• To discuss emerging insights into coxib-related risks and mechanisms.

Main Methods:

• Literature review of pharmacological data.
• Analysis of clinical and preclinical studies on coxib effects.
• Examination of biochemical mechanisms underlying COX inhibition.

Main Results:

• Selective COX-2 inhibitors may reduce gastrointestinal risks but can delay ulcer healing and increase risks when combined with aspirin.
• Coxibs can compromise renal function, cause edema, and hypertension, similar to traditional NSAIDs.
• Despite theoretical benefits, coxibs can increase bleeding risk with anticoagulants and may promote a prothrombotic state, increasing cardiovascular risk.

Conclusions:

• Selective COX-2 inhibition presents complex interactions with physiological systems.
• The clinical application of coxibs requires careful consideration of potential adverse effects and drug interactions.
• Further research is needed to fully elucidate the long-term consequences and mechanisms of selective COX-2 inhibition.